Emerging drugs for respiratory syncytial virus infection

Pulmonary V 4+    T Cells Have Proinflammatory and Antiviral Effects in Viral Lung Disease

(2014) J. Dodd et al.   JOURNAL OF IMMUNOLOGY

Motavizumab

(2009) A. Madaan   DRUGS OF THE FUTURE

The Burden of Respiratory Syncytial Virus Infection in Young Children

(2009) Caroline Breese Hall et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evidence of a Causal Role of Winter Virus Infection during Infancy in Early Childhood Asthma

(2008) Pingsheng Wu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV)

(2008) J DEVINCENZO et al.   ANTIVIRAL RESEARCH

Selection of a Respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate. 2. Discovery of a Morpholinopropylaminobenzimidazole Derivative (TMC353121)

(2008) Jean-François Bonfanti et al.   JOURNAL OF MEDICINAL CHEMISTRY

Respiratory Syncytial Virus Activates Innate Immunity through Toll-Like Receptor 2

(2008) M. R. Murawski et al.   JOURNAL OF VIROLOGY

Alveolar Macrophages Are a Major Determinant of Early Responses to Viral Lung Infection but Do Not Influence Subsequent Disease Development

(2008) P. K. Pribul et al.   JOURNAL OF VIROLOGY

Inhibition of Respiratory Syncytial Virus Infections With Morpholino Oligomers in Cell Cultures and in Mice

(2008) Shen-Hao Lai et al.   MOLECULAR THERAPY